MACROGENICS INC

MacroGenics, Inc. is a clinical-stage biopharmaceutical company that develops antibody-based therapeutics for cancer treatment. Utilizing proprietary multi-specific platforms such as DART and TRIDENT alongside licensed antibody-drug conjugate technologies, the company designs therapeutics for solid tumors and hematologic malignancies. Its pipeline includes investigational candidates like lorigerlimab, MGC026, and MGC028. Beyond proprietary drug development, the company generates revenue and collaborative funding by out-licensing product candidates to global biopharmaceutical partners and providing contract development and manufacturing services to external clients and commercial collaborators.

The company operates a commercial-scale current good manufacturing practice (cGMP) antibody production facility situated at its headquarters in Maryland. It maintains a worldwide patent presence, holding 58 issued patents and 24 pending applications in the United States, as well as 681 issued patents and 283 pending applications across various international jurisdictions. MacroGenics also engages in strategic drug development partnerships with major international pharmaceutical enterprises, including collaborations supporting global product development and commercialization initiatives.

Summary of the business section of Macrogenics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of February 28, 2026, we had 293 full-time employees, 245 of whom were primarily engaged in research, development and manufacturing activities, an d 61 of whom had an M.D.”